title: Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.
abstract: BACKGROUND
  Early diagnosis is important for the outcome of lupus nephritis (LN). However, the pathological type of lupus nephritis closely related to the clinical manifestations; therefore, the treatment of lupus nephritis depends on the different pathological types.
  
  
  OBJECTIVE
  To assess the level of monocyte chemotactic protein (MCP-1), fractalkine (Fkn), and receptor for advanced glycation end product (RAGE) in different pathological types of lupus nephritis and to explore the value of these biomarkers for predicting the prognosis of lupus nephritis.
  
  
  METHODS
  Patients included in this study were assessed using renal biopsy. Class III and class IV were defined as the proliferative group, class V as non-proliferative group, and class V+III and class V+IV as the mixed group. During the follow-up, 40 of 178 enrolled patients had a poor response to the standard immunosuppressant therapy. The level of markers in the different response groups was tested.
  
  
  RESULTS
  The levels of urine and serum MCP-1, urine and serum fractalkine, and serum RAGE were higher in the proliferative group, and lower in the non-proliferative group, and this difference was significant. The levels of urine and serum MCP-1 and serum RAGE were lower in the poor response group, and these differences were also significant. The relationship between urine MCP-1 and urine and serum fractalkine with the systemic lupus erythematosus disease activity index was evaluated.
  
  
  CONCLUSIONS
  The concentration of cytokines MCP-1, fractalkine, and RAGE may be correlated with different pathology type of lupus nephtitis. Urine and serum MCP-1 and serum RAGE may help in predicting the prognosis prior to standard immunosuppressant therapy.
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, P.R. China.
authors.forename: Lan
authors.initials: L
authors.lastname: Lan
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, P.R. China.
authors.forename: Fei
authors.initials: F
authors.lastname: Han
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, P.R. China.
authors.forename: Xiabing
authors.initials: X
authors.lastname: Lang
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, P.R. China.
authors.forename: Jianghua
authors.initials: J
authors.lastname: Chen
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood / Q000652:urine; D018932:Chemokine CCL2 / Q000097:blood* / Q000652:urine; D054428:Chemokine CX3CL1 / Q000097:blood* / Q000652:urine; D005260:Female; D006801:Humans; D008181:Lupus Nephritis / Q000097:blood* / Q000473:pathology / Q000652:urine; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood*
chemical_list: D015415:Biomarkers; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D054428:Chemokine CX3CL1; D000067759:Receptor for Advanced Glycation End Products